'Alternative cancer cures': Looking for common ground: The aim of this occasional feature is to highlight different viewpoints on a controversial issue in oncology, by allowing people (eg clinicians, scientists, nurses and patients) to have their say

Lancet Oncology

Volumn 1, Issue 1, 2000, Pages 54-59

  Ernst, Edzard ^a   Cohen, Lorenzo ^b   Gerner, Judy ^c   Baile, Walter ^c   Schraub, Simon ^c   Diamond, John ^c   Ross, Evan ^c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Place of Wellness ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; HUMAN; NEOPLASM;

COMPLEMENTARY THERAPIES; HUMANS; NEOPLASMS;

EID: 0040194095     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00172-8     Document Type: Note

References (12)

1. Risberg T, Lund E, Wist E, et al. Cancer patients' use of nonproven therapy. A 5-year follow-up study. J Clin Oncol. 16:1998;6-12.
2. Ernst E, Willoughby M, Weihmayr TH. Nine possible reasons for choosing complementary medicine. Perfusion. 11:1995;356-359.
3. Hildebrand G. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson. A retrospective view. Altern Ther Health Med. 4:1995;29-37.
4. Lissoni P, Giana L, Zerbini S, et al. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun. 16:1998;27-33.
5. Lissoni P, Barni S, Ardizzoa A. A randomized study with pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer. 73:1994;699-701.
6. Alecu M, Ursaciuc C, Halalau F, et al. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res. 18:1998;4651-4654.
7. Taille A de la, Kayek OR, Buttyan R, et al. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int. 84:1999;845-850.
8. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer. 76:1995;743-749.
9. Ernst E. Only 0.08% of funding for research in NHS goes to complementary medicine. BMJ. 313:1996;882.
10. Ernst E, Wider B. UK medical charities and clinical trials. Br J Gen Pract. 49:1999;755.
11. Alder SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Family Pract. 48:1999;453-458.
12. Newell S, Sanson-Fisher RW. Australian oncologists' self-reported knowledge and attitudes about non-traditional therapies used by cancer patients. Med J Aust. 172:2000;110-113.